Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization

Artificial intelligence (AI) is significantly advancing precision medicine, particularly in the fields of immunogenomics, radiomics, and pathomics. In immunogenomics, AI can process vast amounts of genomic and multi-omic data to identify biomarkers associated with immunotherapy responses and disease...

Full description

Saved in:
Bibliographic Details
Main Authors: Luchen Chang, Jiamei Liu, Jialin Zhu, Shuyue Guo, Yao Wang, Zhiwei Zhou, Xi Wei
Format: Article
Language:English
Published: China Anti-Cancer Association 2025-01-01
Series:Cancer Biology & Medicine
Subjects:
Online Access:https://www.cancerbiomed.org/content/22/1/33
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832098360369086464
author Luchen Chang
Jiamei Liu
Jialin Zhu
Shuyue Guo
Yao Wang
Zhiwei Zhou
Xi Wei
author_facet Luchen Chang
Jiamei Liu
Jialin Zhu
Shuyue Guo
Yao Wang
Zhiwei Zhou
Xi Wei
author_sort Luchen Chang
collection DOAJ
description Artificial intelligence (AI) is significantly advancing precision medicine, particularly in the fields of immunogenomics, radiomics, and pathomics. In immunogenomics, AI can process vast amounts of genomic and multi-omic data to identify biomarkers associated with immunotherapy responses and disease prognosis, thus providing strong support for personalized treatments. In radiomics, AI can analyze high-dimensional features from computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) images to discover imaging biomarkers associated with tumor heterogeneity, treatment response, and disease progression, thereby enabling non-invasive, real-time assessments for personalized therapy. Pathomics leverages AI for deep analysis of digital pathology images, and can uncover subtle changes in tissue microenvironments, cellular characteristics, and morphological features, and offer unique insights into immunotherapy response prediction and biomarker discovery. These AI-driven technologies not only enhance the speed, accuracy, and robustness of biomarker discovery but also significantly improve the precision, personalization, and effectiveness of clinical treatments, and are driving a shift from empirical to precision medicine. Despite challenges such as data quality, model interpretability, integration of multi-modal data, and privacy protection, the ongoing advancements in AI, coupled with interdisciplinary collaboration, are poised to further enhance AI’s roles in biomarker discovery and immunotherapy response prediction. These improvements are expected to lead to more accurate, personalized treatment strategies and ultimately better patient outcomes, marking a significant step forward in the evolution of precision medicine.
format Article
id doaj-art-d574253ffa9c43e3b4673be606f9a6eb
institution Kabale University
issn 2095-3941
language English
publishDate 2025-01-01
publisher China Anti-Cancer Association
record_format Article
series Cancer Biology & Medicine
spelling doaj-art-d574253ffa9c43e3b4673be606f9a6eb2025-02-05T11:20:47ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412025-01-01221334710.20892/j.issn.2095-3941.2024.0376Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimizationLuchen Chang0Jiamei Liu1Jialin Zhu2Shuyue Guo3Yao Wang4Zhiwei Zhou5Xi Wei6Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaDepartment of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaDepartment of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaDepartment of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaDepartment of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaDepartments of Biochemistry and Radiation Oncology, UT Southwestern Medical Center, Dallas 75390, USADepartment of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaArtificial intelligence (AI) is significantly advancing precision medicine, particularly in the fields of immunogenomics, radiomics, and pathomics. In immunogenomics, AI can process vast amounts of genomic and multi-omic data to identify biomarkers associated with immunotherapy responses and disease prognosis, thus providing strong support for personalized treatments. In radiomics, AI can analyze high-dimensional features from computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) images to discover imaging biomarkers associated with tumor heterogeneity, treatment response, and disease progression, thereby enabling non-invasive, real-time assessments for personalized therapy. Pathomics leverages AI for deep analysis of digital pathology images, and can uncover subtle changes in tissue microenvironments, cellular characteristics, and morphological features, and offer unique insights into immunotherapy response prediction and biomarker discovery. These AI-driven technologies not only enhance the speed, accuracy, and robustness of biomarker discovery but also significantly improve the precision, personalization, and effectiveness of clinical treatments, and are driving a shift from empirical to precision medicine. Despite challenges such as data quality, model interpretability, integration of multi-modal data, and privacy protection, the ongoing advancements in AI, coupled with interdisciplinary collaboration, are poised to further enhance AI’s roles in biomarker discovery and immunotherapy response prediction. These improvements are expected to lead to more accurate, personalized treatment strategies and ultimately better patient outcomes, marking a significant step forward in the evolution of precision medicine.https://www.cancerbiomed.org/content/22/1/33artificial intelligencetumor immune microenvironmentgenomicstranscriptomicsradiomicspathomics
spellingShingle Luchen Chang
Jiamei Liu
Jialin Zhu
Shuyue Guo
Yao Wang
Zhiwei Zhou
Xi Wei
Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
Cancer Biology & Medicine
artificial intelligence
tumor immune microenvironment
genomics
transcriptomics
radiomics
pathomics
title Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
title_full Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
title_fullStr Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
title_full_unstemmed Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
title_short Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
title_sort advancing precision medicine the transformative role of artificial intelligence in immunogenomics radiomics and pathomics for biomarker discovery and immunotherapy optimization
topic artificial intelligence
tumor immune microenvironment
genomics
transcriptomics
radiomics
pathomics
url https://www.cancerbiomed.org/content/22/1/33
work_keys_str_mv AT luchenchang advancingprecisionmedicinethetransformativeroleofartificialintelligenceinimmunogenomicsradiomicsandpathomicsforbiomarkerdiscoveryandimmunotherapyoptimization
AT jiameiliu advancingprecisionmedicinethetransformativeroleofartificialintelligenceinimmunogenomicsradiomicsandpathomicsforbiomarkerdiscoveryandimmunotherapyoptimization
AT jialinzhu advancingprecisionmedicinethetransformativeroleofartificialintelligenceinimmunogenomicsradiomicsandpathomicsforbiomarkerdiscoveryandimmunotherapyoptimization
AT shuyueguo advancingprecisionmedicinethetransformativeroleofartificialintelligenceinimmunogenomicsradiomicsandpathomicsforbiomarkerdiscoveryandimmunotherapyoptimization
AT yaowang advancingprecisionmedicinethetransformativeroleofartificialintelligenceinimmunogenomicsradiomicsandpathomicsforbiomarkerdiscoveryandimmunotherapyoptimization
AT zhiweizhou advancingprecisionmedicinethetransformativeroleofartificialintelligenceinimmunogenomicsradiomicsandpathomicsforbiomarkerdiscoveryandimmunotherapyoptimization
AT xiwei advancingprecisionmedicinethetransformativeroleofartificialintelligenceinimmunogenomicsradiomicsandpathomicsforbiomarkerdiscoveryandimmunotherapyoptimization